MX2021011154A - Composiciones y metodos para tratar formas de cancer con receptores de androgenos positivos. - Google Patents
Composiciones y metodos para tratar formas de cancer con receptores de androgenos positivos.Info
- Publication number
- MX2021011154A MX2021011154A MX2021011154A MX2021011154A MX2021011154A MX 2021011154 A MX2021011154 A MX 2021011154A MX 2021011154 A MX2021011154 A MX 2021011154A MX 2021011154 A MX2021011154 A MX 2021011154A MX 2021011154 A MX2021011154 A MX 2021011154A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- androgen receptor
- compositions
- receptor positive
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819472P | 2019-03-15 | 2019-03-15 | |
| US201962819476P | 2019-03-15 | 2019-03-15 | |
| US201962819490P | 2019-03-15 | 2019-03-15 | |
| US201962819482P | 2019-03-15 | 2019-03-15 | |
| US201962819487P | 2019-03-15 | 2019-03-15 | |
| US201962821660P | 2019-03-21 | 2019-03-21 | |
| PCT/US2019/039936 WO2020006483A1 (fr) | 2018-06-29 | 2019-06-28 | Inhibition de la protéine de liaison à creb (cbp) |
| PCT/US2020/022823 WO2020190792A1 (fr) | 2019-03-15 | 2020-03-13 | Compositions et procédés pour traiter des formes positives de récepteurs des androgènes du cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021011154A true MX2021011154A (es) | 2021-10-22 |
Family
ID=72521203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021011154A MX2021011154A (es) | 2019-03-15 | 2020-03-13 | Composiciones y metodos para tratar formas de cancer con receptores de androgenos positivos. |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3938365A4 (fr) |
| CN (1) | CN113784967A (fr) |
| AU (1) | AU2020241709A1 (fr) |
| BR (1) | BR112021018266A2 (fr) |
| CA (1) | CA3132995A1 (fr) |
| MX (1) | MX2021011154A (fr) |
| WO (1) | WO2020190792A1 (fr) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010110380A1 (fr) * | 2009-03-27 | 2010-09-30 | 興和株式会社 | Composé de pipéridine condensé et agent pharmaceutique le contenant |
| CN103038229B (zh) * | 2010-05-26 | 2016-05-11 | 桑诺维恩药品公司 | 杂芳基化合物及其使用方法 |
| MX370535B (es) * | 2013-11-18 | 2019-12-17 | Forma Therapeutics Inc | Compuestos de tetrahidroquinolina como inhibidores del bromodominio extra terminal y bromo (bet) y el uso de los mismos en el tratamiento de cáncer. |
| EP3632915A1 (fr) * | 2014-11-27 | 2020-04-08 | Genentech, Inc. | Composés 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine utilisés comme inhibiteurs de cbp et/ou de ep300 |
| WO2017197056A1 (fr) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles |
| EP3681885B1 (fr) * | 2017-09-15 | 2024-02-28 | Forma Therapeutics, Inc. | Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300 |
| MX2023013508A (es) * | 2018-06-29 | 2023-12-13 | Forma Therapeutics Inc | Inhibicion de la proteina de union a creb (cbp). |
-
2020
- 2020-03-13 EP EP20774663.7A patent/EP3938365A4/fr active Pending
- 2020-03-13 BR BR112021018266A patent/BR112021018266A2/pt unknown
- 2020-03-13 AU AU2020241709A patent/AU2020241709A1/en active Pending
- 2020-03-13 MX MX2021011154A patent/MX2021011154A/es unknown
- 2020-03-13 CA CA3132995A patent/CA3132995A1/fr active Pending
- 2020-03-13 WO PCT/US2020/022823 patent/WO2020190792A1/fr unknown
- 2020-03-13 CN CN202080021617.5A patent/CN113784967A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3938365A4 (fr) | 2023-01-25 |
| CN113784967A (zh) | 2021-12-10 |
| WO2020190792A1 (fr) | 2020-09-24 |
| CA3132995A1 (fr) | 2020-09-24 |
| EP3938365A1 (fr) | 2022-01-19 |
| BR112021018266A2 (pt) | 2022-02-01 |
| AU2020241709A1 (en) | 2021-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019222112A8 (fr) | Inhibiteurs de mcl-1 | |
| JOP20220008A1 (ar) | مثبطات parp1 | |
| PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
| GEP20237506B (en) | Pcsk9 antagonist compounds | |
| PH12019502132A1 (en) | Combination therapy for the treatment or prevention of tumours | |
| WO2018022668A3 (fr) | Compositions neuromodulatrices et méthodes associées de traitement du cancer | |
| MX2019008207A (es) | Métodos para tratar el cáncer con anticuerpos anti-pd-1. | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| PH12020552214A1 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| MX2021010252A (es) | Inhibidores del receptor de glucocorticoides. | |
| MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| MX2022001004A (es) | Inhibidores de enzimas. | |
| MX2017010422A (es) | Imidazolil enonas triciclicas como moduladores de inflamacion antioxidantes. | |
| ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
| MX2021011154A (es) | Composiciones y metodos para tratar formas de cancer con receptores de androgenos positivos. | |
| MX2021011699A (es) | Derivados de quinolina y su uso para el tratamiento del cancer. | |
| MX2020013805A (es) | Derivados de piridopirimidinona para uso como inhibidores de axl. | |
| MX2020010156A (es) | Inhibidores de la secrecion de proteina cdp. | |
| MX2019003368A (es) | Agentes anticancerigenos y preparacion de los mismos. | |
| MX2022007634A (es) | Inhibidores de egfr. | |
| MX2022000781A (es) | Triterpenoides sintéticos heteroaromáticos sustituidos polarmente en c17, y métodos de uso de los mismos. | |
| EA202092539A1 (ru) | Модуляторы nlrp3 | |
| EA202091694A1 (ru) | Ингибиторы pd-1/pd-l1 | |
| WO2019039937A8 (fr) | Polythérapie pour traitement du cancer |